ReviewFrontiers in oncology2025
Bibliometrics and scientometrics analysis of exosomes relevance in hepatocellular carcinoma (2014-2024).
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status and Emerging Trends in Global Research on Liposome Therapy for Hepatocellular Carcinoma: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Exosomes have emerged as pivotal players in the pathogenesis, progression, and treatment of hepatocellular carcinoma (HCC), establishing them as a major research focus in recent years. This bibliometric analysis maps the knowledge evolution and quantifies research trends in exosome-associated HCC studies from 2014 to 2024. Methods: We retrieved relevant publications (2014-2024) from the Web of Science Core Collection (WoSCC) database and conducted bibliometric analyses using CiteSpace, VOSviewer, and R software. Results: The analysis encompassed 1,120 publications (714 research articles and 406 reviews), originating from 60 countries/regions and 4,035 institutions, published in 388 journals, and authored by 6,989 authors. China emerged as the most productive country, followed by the United States. The most prolific journals were the International Journal of Molecular Sciences and Frontiers in Oncology, while Fudan University ranked as the most productive institution. Trend analysis indicates that future HCC exosome research will concentrate on: the development and application of exosomes as HCC biomarkers, optimizing exosomes as drug delivery vehicles, investigating tumor treatment resistance, and exploring exosome-mediated immunotherapeutic strategies for HCC to facilitate their clinical application. Conclusion: Current evidence demonstrates that the field of HCC exosome research is in a phase of rapid development, with its potential in both basic research and clinical translation continually being explored. Through bibliometric analysis, this study identifies key trends and emerging directions in HCC exosome research from 2014 to 2024, offering insights into current research priorities and potential innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.